[go: up one dir, main page]

JP2002030000A - Fundamental treatment for common cold - Google Patents

Fundamental treatment for common cold

Info

Publication number
JP2002030000A
JP2002030000A JP2000250327A JP2000250327A JP2002030000A JP 2002030000 A JP2002030000 A JP 2002030000A JP 2000250327 A JP2000250327 A JP 2000250327A JP 2000250327 A JP2000250327 A JP 2000250327A JP 2002030000 A JP2002030000 A JP 2002030000A
Authority
JP
Japan
Prior art keywords
upper respiratory
treatment
common cold
cold
inhaled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000250327A
Other languages
Japanese (ja)
Inventor
Saburo Yasuda
三郎 安田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP2000250327A priority Critical patent/JP2002030000A/en
Priority to AU2001274552A priority patent/AU2001274552A1/en
Priority to PCT/JP2001/005225 priority patent/WO2002005802A1/en
Publication of JP2002030000A publication Critical patent/JP2002030000A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Respiratory Apparatuses And Protective Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

PROBLEM TO BE SOLVED: To provide the root-basically therapeutic treatment for common cold and pollinosis. SOLUTION: In this therapeutic treatment for common cold or pollinosis, a medicine at such a level of anesthetizing the physiological function of upper respiratory tract mucous cells is gradually released or inhaled. As a medicine for this treatment, are suitably cited any volatile compounds that dysfunction the physiological function of upper respiratory tract mucous cells, for example, monohydric alcohol (ethanol, butanol, menthol or the like), volatile sulfide (allyl sulfide or the like), volatile acid or base (hydrochloric acid, ammonia or the like), trihalomethanes (chloroform or the like).

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[発明の目的] [産業上の利用分野]本発明は、風邪の根本的な治療方
法や、花粉症の治療方法に関する。 {出願した経緯}本発明者は、上気道粘膜に軽い痛みを
覚える程度の高濃度の薬剤を吸入すれば、今まで言われ
ているような鼻水を止めると言った対症治療ばかりでな
く、ウイルスの増殖を阻止して解熱すると言った根本治
療することを発見して特願平8−530885をした
が、拒絶審決(平成12年5268号)で、上気道粘膜
細胞を症害させる程度の濃度数値が示されていないとの
指摘を受け、薬剤の濃度の具体的表示としては、上気道
粘膜に軽い痛みを覚える程度の高濃度である旨を追加
し、数値限定的趣旨を加味して新出願した。 {従来の技術}メントールを徐放するマスクが、風邪や
花粉症の対症治療用として市販されているが、鼻詰まり
を治したり、沈静作用等の対症治療を目的とした市販の
マスクでは、消費者に不快感を与えるのを避けるため、
上気道粘膜に軽い痛みを覚える程度の高濃度の薬剤蒸気
を吸入するように製作されていない。また、拒絶審決
(平成12年5268号)で引用された、「特開平3−
143457号広報」記載の技術も治療効果を発揮する
としているが、実施例から推測するに、2倍以上の薬剤
含侵量でないと気道粘膜に軽い痛みを覚える程度の高濃
度の薬剤蒸気は吸入できないので風邪を根本治療できな
い。さらに、2000年中に、インフルエンザの根本治
療薬として、上気道粘膜細胞とインフルエンザウイルス
とを結合させているシアル酸を切り離す酵素を阻害する
炭化水素の吸入薬が、日本でも発売される予定である
が、この吸入薬はインフルエンザ等一部の風邪ウイルス
にしか効果がない。又、薬剤が粘液に流さて薬効が減少
し、寝たきり老人・乳幼児には薬剤粉を吸入し辛い。本
発明にかかる治療方法は、上記のような欠点はない。
[Object of the Invention] [Field of Industrial Application] The present invention relates to a method for treating a common cold and a method for treating hay fever. } Background of application} The present inventor is not only symptomatic treatment that said that if a drug is inhaled to the upper respiratory mucosa at a high concentration enough to cause mild pain, it will stop the runny nose as it has been said, He discovered that he would treat radically, saying that he could prevent the growth and fever of his, and filed Japanese Patent Application No. 8-530885. However, in a rejection decision (No. 5268, 2000), the concentration was such that he could damage upper mucosa cells. In response to the indication that the numerical value was not indicated, a specific indication of the concentration of the drug was added, stating that the concentration was high enough to cause mild pain in the upper respiratory mucosa, and taking into account the purpose of limiting the numerical value. Filed. {Conventional technology} Masks that release menthol slowly are marketed for the treatment of colds and hay fever.However, commercially available masks for the treatment of nasal congestion and for the treatment of symptoms such as sedation are not used. To avoid discomfort to the person,
It is not designed to inhale a high concentration of drug vapor that causes mild pain to the upper respiratory mucosa. In addition, “Japanese Unexamined Patent Application Publication No.
Although the technology described in "143457 Public Information" is also expected to exhibit a therapeutic effect, it is inferred from the examples that if the drug content is not more than twice as high, drug vapor with a high concentration enough to cause slight pain to the respiratory tract mucosa is inhaled. I can not cure the cold because I can not do it. In addition, a hydrocarbon inhaler that inhibits the enzyme that cuts off sialic acid that binds the upper respiratory mucosal cells to the influenza virus will be launched in Japan as a radical treatment for influenza during the year 2000. However, this inhalant is effective only for some cold viruses such as influenza. In addition, the drug is spilled into the mucus to reduce the medicinal effect, and it is difficult for bedridden elderly people and infants to inhale the drug powder. The treatment method according to the present invention does not have the above-mentioned disadvantages.

【0002】[発明の構成] {課題を解決するための手段}課題を解決するための手
段として、吸入すべき薬剤の濃度を上気道粘膜細胞を生
理的に機能不全させる程度の濃度まで上げる。薬剤とし
ては、1価のアルコール(エタノール・ブチルアルコー
ル・メントール等)揮発性の硫化物(硫化アリル等)揮
発性の酸・塩基化合物(塩酸・アンモニア等)トリハロ
メタン(クロロホルム等)あらゆる上気道粘膜細胞を生
理的に機能不全させる揮発性化合物が考えられる。使用
可能薬剤は無数に有りその全てに適正な薬剤濃度を記載
することは不可能だが、概ね、上気道粘膜に軽い痛みを
覚える程度の高濃度であれば、風邪を根本的治療できる
と考えてよい。 {作用・効果}風邪とは、気道粘膜での炎症を言い、大
部分はウイルスにより発病する。この風邪ウイルスはD
NAを持たず、生きた哺乳類・鳥類の上気道粘膜細胞に
付着し、細胞内に進入して増殖を始める。このため、上
気道粘膜細胞が生理的に機能不全になると、風邪ウイル
スは増殖できない。風邪ウイルスは体温では数時間で生
命体としての活性を失うので、インフルエンザ等の風邪
を根本的に治療できる。本発明にかかる風邪根本治療法
は、230種に及ぶ全ての風邪ウイルスに、原理的に有
効である。又、酵素阻害剤を使っていないので、前記し
た酵素阻害剤と違い、他剤併用による副作用が殆ど考え
られない。又、マスクに装着する形式を取ることができ
るので、上記に示した薬剤粉を定時に吸入するインフル
エンザ治療法より、常時上気道粘膜細胞を生理的に機能
不全させることができ、薬剤が粘液に流されないので効
果的である。インフルエンザで死亡し易い老人・乳幼児
にも、呼吸とともに吸入させることができる。本発明
は、世界で初めて、全てのウイルス性の風邪を完全に根
本治療する方法を開示したものである。さらに、花粉等
の坑原物質の吸収も阻害されるため、イムノコンプレッ
クスの発生を防ぎ花粉症を時限的に治療する。即ち、本
治療法を実施している間は発熱・鼻水等を治療する。
[Constitution of the Invention] {Means for Solving the Problems} As a means for solving the problems, the concentration of the drug to be inhaled is increased to a level that causes the upper respiratory tract mucosal cells to malfunction physiologically. Drugs include monohydric alcohols (ethanol, butyl alcohol, menthol, etc.) volatile sulfides (allyl sulfide, etc.) volatile acid and base compounds (hydrochloric acid, ammonia, etc.) trihalomethane (chloroform, etc.) All upper respiratory mucosal cells Volatile compounds that render Physiologically dysfunctional are considered. There are innumerable drugs available, and it is impossible to list the appropriate drug concentration for all of them.However, in general, it is considered that a high concentration enough to cause slight pain in the upper respiratory mucosa can fundamentally treat colds. Good. {Effects} A cold refers to inflammation in the mucous membrane of the respiratory tract and is mostly caused by a virus. This cold virus is D
Without NA, it attaches to the upper respiratory tract mucosal cells of living mammals and birds, enters the cells and starts to proliferate. Thus, if the upper respiratory tract mucosal cells become physiologically dysfunctional, the cold virus cannot multiply. Since the cold virus loses its activity as an organism within a few hours at body temperature, it can fundamentally treat a cold such as influenza. The method for treating a common cold according to the present invention is effective in principle for all 230 cold viruses. Further, since no enzyme inhibitor is used, unlike the above-mentioned enzyme inhibitors, side effects due to the combined use of other drugs are hardly considered. In addition, since it is possible to take the form of being attached to a mask, the upper respiratory tract mucosal cells can be always physiologically dysfunctional and the drug can be converted into mucus, compared to the influenza treatment method in which the above-mentioned drug powder is inhaled at regular intervals. It is effective because it is not washed away. It can be inhaled along with breathing even for elderly people and infants who easily die from influenza. The present invention discloses, for the first time in the world, a method for completely treating all viral colds completely. In addition, absorption of antifermental substances such as pollen is also inhibited, so that the occurrence of immunocomplex is prevented and hay fever is treated in a timely manner. That is, while the treatment is being performed, fever and runny nose are treated.

【0003】[実施例]使用薬剤として、扱い安さ・低
コスト・無害性から、メントールが適当と考えられる
が、麻酔性を有する1価のアルコール(エチルアルコー
ル等)でもよい。上気道粘膜に軽い痛みを覚える程度の
高濃度のメントール蒸気を徐放的に吸入すると、インフ
ルエンザ・パラインフルエンザ・アデノ等の風邪を8時
間程で解熱・根本治療できる。咳を伴う風邪では,上気
道粘膜細胞の再生に数日かかるので、熱が下がっても、
数日間咳がでるが、全身倦怠感は取れている。花粉症も
吸入している間は鼻水が止まる。徐放的に吸入すると、
効果的であり、過去の出願例を参考にしてマスクに装着
する形式が望ましい。どの様にマスクに装着するかにつ
いては、過去の特許・実用新案出願を参考にするとよ
い。風邪の初期に吸入すればなお効果的であり、上気道
粘膜細胞に異常を感じた時、又は、鼻水が出始めた時で
あれば、低濃度のメントール蒸気でも根本治療できる
が、これ以後(熱がでてから)は上気道粘膜に軽い痛み
を覚える程度の高濃度のメントール蒸気を徐放的に吸入
しなければ、根本治療できない。このことから、卵酒は
前述の原理を利用したものであるが、極めて初期の風邪
にしか利かない。上気道粘膜に軽い痛みを覚える程度の
高濃度のメントール蒸気を徐放的に吸入すると、高熱は
1日で下がるが、37度C前半の微熱が数日続くことが
ある。又、香港で検出されたインフルエンザAH5型
(極めて毒性が強くワクチンの製造が困難・3人に1人
が死亡)にも、原理的に効果を示す。特にインフルエン
ザAH5型で死亡例が多い寝たきり老人・乳幼児には前
記した米国のグラクソ社製のシアル酸を切り離す酵素を
阻害する炭化水素の吸入薬(回復が2日程度早い効果)
が使えないので、マスクによる吸入ができる本治療法は
有効である。炭化水素系酵素阻害剤の吸入薬(朝・昼・
晩の日に3回吸入)は薬剤粉であるので徐放的に吸入で
きないので、吸入時以外は上気道粘膜細胞表面の粘液に
より流され、効果は半減する。本治療法は対策が急がれ
るインフルエンザAH5型に最も有効な風邪治療法と言
える。酵素阻害剤は他の薬剤(坑癌剤等)と併用した時
の副作用が心配で有る。
[Example] Menthol is considered to be suitable as a drug to be used because of its ease of handling, low cost and harmlessness, but monohydric alcohol having anesthetic properties (such as ethyl alcohol) may be used. By inhaling the menthol vapor at a high concentration enough to cause mild pain in the upper respiratory mucosa, the cold such as influenza, parainfluenza, adeno, etc. can be alleviated in about 8 hours. In a cold with a cough, it takes a few days to regenerate the upper respiratory mucosal cells.
He has coughed for several days, but his general malaise has been removed. Runny nose stops while inhaling hay fever. When inhaled slowly,
It is effective, and it is desirable to adopt a form in which the mask is attached to a mask with reference to the past application examples. It is recommended to refer to past patent and utility model applications for how to attach the mask. It is still effective if inhaled in the early stage of a cold, and if you feel abnormalities in the upper respiratory tract mucosal cells, or when you have a runny nose, you can use low-concentration menthol vapors for the radical treatment. After the fever has developed), it is not possible to treat radically unless high-concentration menthol vapor is inhaled slowly enough to cause slight pain in the upper respiratory mucosa. From this, egg liquor is based on the principle described above, but is only useful for very early colds. When inhaling menthol vapor at a high concentration that causes mild pain to the upper respiratory mucosa in a sustained-release manner, the high fever can be reduced in one day, but a slight fever in the first half of 37 ° C may continue for several days. It is also effective in principle against influenza AH5 detected in Hong Kong (very toxic and difficult to produce vaccine, one out of three deaths). In particular, bedridden elderly people and infants who have died of influenza AH5 who have many deaths are inhaled by the above-mentioned Glaxo, Inc., a hydrocarbon inhalant that inhibits the enzyme that cuts off sialic acid.
This treatment, which can be inhaled with a mask, is effective because it cannot be used. Inhalants of hydrocarbon enzyme inhibitors (morning / noon /
(3 inhalations in the evening) is a drug powder and cannot be inhaled in a sustained-release manner. This treatment can be said to be the most effective cold treatment for influenza AH5, for which measures are urgently needed. Enzyme inhibitors are worried about side effects when used in combination with other drugs (such as anticancer drugs).

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A61K 31/045 A61K 31/045 31/095 31/095 33/02 33/02 33/20 33/20 ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme coat ゛ (Reference) A61K 31/045 A61K 31/045 31/095 31/095 33/02 33/02 33/20 33/20

Claims (1)

【特許請求の範囲】[Claims] 【請求項1】上気道粘膜細胞の生理機能を麻痺させる程
度の濃度の薬剤を徐放・吸入して風邪を根本治療し、花
粉症を時限的に治療する方法。
(1) A method for treating a cold by radically releasing / inhaling a drug at a concentration sufficient to paralyze the physiological function of upper respiratory mucosal cells, and treating pollinosis in a timely manner.
JP2000250327A 2000-07-17 2000-07-17 Fundamental treatment for common cold Pending JP2002030000A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2000250327A JP2002030000A (en) 2000-07-17 2000-07-17 Fundamental treatment for common cold
AU2001274552A AU2001274552A1 (en) 2000-07-17 2001-06-19 Method of fundamentally treating common cold
PCT/JP2001/005225 WO2002005802A1 (en) 2000-07-17 2001-06-19 Method of fundamentally treating common cold

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000250327A JP2002030000A (en) 2000-07-17 2000-07-17 Fundamental treatment for common cold

Publications (1)

Publication Number Publication Date
JP2002030000A true JP2002030000A (en) 2002-01-29

Family

ID=18739923

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000250327A Pending JP2002030000A (en) 2000-07-17 2000-07-17 Fundamental treatment for common cold

Country Status (3)

Country Link
JP (1) JP2002030000A (en)
AU (1) AU2001274552A1 (en)
WO (1) WO2002005802A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60318237T2 (en) 2002-10-24 2008-12-18 Immupharm A/S PHARMACEUTICAL COMPOSITIONS CONTAINING FLAVONOIDS AND MENTHOL
EP2014333A1 (en) 2007-07-12 2009-01-14 Hakiman Shargh Research Company Use of cooling agents for treatment or prevention of lacrimation or eye burning
CN102397361A (en) * 2011-11-26 2012-04-04 苏州派腾生物医药科技有限公司 Preparation method of granules for treating cold and relieving cough
EP3356356B1 (en) 2015-10-01 2021-05-26 Firmenich Incorporated Compounds useful as modulators of trpm8
CN111419906A (en) * 2020-03-04 2020-07-17 柳保来 Medicament for treating neocoronary pneumonia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62101259A (en) * 1985-10-25 1987-05-11 安田 三郎 Cold treatment apparatus
JPS63209666A (en) * 1987-02-27 1988-08-31 帝三製薬株式会社 Menthol-containing mask
JPH01313062A (en) * 1988-06-14 1989-12-18 Kao Corp External remedy for cold
JPH07148280A (en) * 1993-10-04 1995-06-13 Koki Bussan Kk Mask
JPH10286318A (en) * 1995-04-12 1998-10-27 Saburo Yasuda Mask for medical treatment of cold

Also Published As

Publication number Publication date
WO2002005802A1 (en) 2002-01-24
AU2001274552A1 (en) 2002-01-30

Similar Documents

Publication Publication Date Title
GB2430623A (en) Medicaments for treating chronic respiratory disease
WO2022111497A1 (en) Application of iodine in preparation of drugs for preventing and treating respiratory tract infectious diseases
JP2002030000A (en) Fundamental treatment for common cold
CN100518775C (en) Medicine composition for treating cough and asthma and preparation thereof
JP7369523B2 (en) Treatment of moderate to severe influenza
RU2757360C1 (en) Use of a phospholipid emulsion containing an effective amount of dihydroquercetin, lecithin and glycine for the treatment of inflammatory diseases of the respiratory system
CA2701388C (en) Calcium glycerophosphate for treating and preventing respiratory diseases or conditions
Ezz et al. Disinfection of SARS-COV-2 (COVID-19) in human respiratory tract by controlled ethanol vapor inhalation combined with Asprin
CN1106304A (en) Health gauze mask for prevention of allergy and infection
WO2022063320A1 (en) Composition for inhibiting respiratory virus and respiratory virus prevention and treatment method
US20060210482A1 (en) Chemical composition and method for cold and sinus relief
EP2593119B1 (en) Polysaccharide polymer from the seeds of the tamarind tree for use in treating dry cough
RU2766246C1 (en) Method for treatment and rehabilitation of patients after acute respiratory viral infections
RU2824607C2 (en) 2-(imidazol-4-yl)-ethanamide of pentanedioic acid or pharmaceutically acceptable salt thereof for treating covid-19 and symptoms thereof
RU2143264C1 (en) Method of treatment of patients with tracheitis
Liu Five supplementary therapies for COVID-19
Sari et al. Implementation of simple inhalation therapy to improve airway clearance in children with bronchopneumonia
CN120093055A (en) A mask capable of sustained-release of medicine and a medicine core package
RU1782591C (en) Medicinal agent influenza prevention by inhaling through the nose
SU701639A1 (en) Method of bronchial asthma therapy
US20220096407A1 (en) Composition for inhibiting respiratory viruses and respiratory virus prevention and treatment method
TW202310855A (en) Treatment of covid-19 and other viral infections, bacterial infections, injuries, ards, or conditions that result in acute elevation of substance p levels causing pathological activation of the cytokine system using nitrous oxide or any of the inhaled anesthetics
Jamshald Evidence for the cure of flu through nose breathing
Vogel et al. Zopiclone-associated respiratory depression
Bhattacharya et al. Old Drug In New Shape With Tmp-Smx For Cure Covid 19

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040712

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20050802